YOLFTbeta
Gabather AB (publ)

Gabather AB (publ)

GABA · ST · Healthcare / Drug Manufacturers - Specialty & Generic

0.0182SEK-0.00 (-3.19%)

Price History

Full chart

Market Stats

Previous Close0.0188
Open0.0188
Day Range0.0162 – 0.0188
52-Week Range0.023 – 0.068
Volume1.83M
Market Cap15.75M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.01
Dividend Yield0.00%
Beta-0.75
50-Day Avg0.0307
200-Day Avg0.0355

About

Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. The company focuses on developing GT-002, a pro-cognitive drug candidate for the treatment of Alzheimer's disease, schizophrenia, and major depressive disorders. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje, Sweden.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEODr. Michael-Robin Witt
  • Employees2
  • HeadquartersForskargatan 20J, Södertälje, Sweden, 151 36, Sweden
  • Websitehttps://www.gabather.com

Leadership

  • Dr. Michael-Robin WittCEO, CSO & Director
  • Dr. Christine RyanChief Operating Officer

Financials

Income Statement

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--476.27K3.01M45.94K3700-23.00K0000
Growth (%)---+532.24%-98.47%-99.19%-100.00%-+100.00%---
Cost of Revenue71.63K4.60K59.05K65.33K84.18K84.18K------
Gross Profit-71.63K-4.60K-59.05K-65.33K-84.18K-84.18K------
Gross Margin---12.40%-2.17%-183.24%-22751.35%------
Operating Expense2.51M5.96M7.84M9.87M20.20M14.19M------
Operating Income-2.59M-5.97M-7.89M-9.94M-20.29M-14.27M-14.64M-16.99M-8.55M-9.47M-7.78M-4.53M
Operating Margin---1657.56%-330.01%-44164.13%-3857895.41%-73873.91%----
EBITDA-2.58M-5.94M-7.84M-9.87M-20.20M-14.19M-14.58M-16.99M-8.55M37.00K-7.75M-4.53M
EBITDA Margin---1645.10%-327.85%-43981.28%-3835405.41%-73873.91%----
Net Income-2.59M-5.96M-7.89M-9.94M-20.31M-14.28M-14.95M-17.00M-8.54M-9.44M-7.75M-4.65M
Net Income Margin---1657.49%-330.04%-44218.55%-3859884.05%-73908.70%----
R&D-4.60K----------
Interest Expense-1.04K21657925.08K7.36K7.00K4.00K3.00K-0155.00K
Interest Expense % of Total Revenue--0.05%0.02%54.58%1988.65%--17.39%----

Balance Sheet

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets9.16M13.51M34.75M48.18M18.16M46.07M32.16M15.39M6.75M7.36M1.83M3.83M
Total Liabilities525.26K727.31K1.56M2.42M2.29M2.48M3.31M4.43M3.31M6.88M6.01M4.69M
Total Equity8.63M12.79M33.19M45.76M15.87M43.59M27.91M10.96M3.44M486.00K-4.17M-863.00K
Cash7.98M10.08M27.89M36.70M16.65M44.90M30.92M14.85M6.27M1.11M878.00K3.14M
Net Debt-7.98M-10.08M-27.89M-36.70M-16.65M-44.90M-30.92M-14.85M-6.27M-1.11M-878.00K-3.14M

Cash Flow

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.60K-5.47M-7.09M-9.68M-20.05M-13.68M-13.69M-16.12M-9.60M-11.64M-3.33M-7.22M
Investing Cash Flow-968.3-2.54M-3.35M-4.03M-43.93K-73.90K-289.00K-----
Financing Cash Flow15.54K10.12M28.29M22.51M42.22M42.01M46.00K46.00K1.02M6.49M3.09M9.49M
Capital Expenditure02.54M3.35M4.03M43.93K73.90K289.00K345.00K0000
Free Cash Flow-2.60K-8.01M-10.44M-13.71M-20.10M-13.76M-13.98M-16.12M-9.60M-11.64M-3.33M-7.22M
FCF to OCF100.00%146.40%147.29%141.64%100.22%100.54%102.11%100.00%100.00%100.00%100.00%100.00%

Earnings

Report DateDec 31, 2014Dec 31, 2015Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Aug 28, 2020Nov 5, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Jun 28, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024May 28, 2025Aug 28, 2025Nov 27, 2025Feb 26, 2026May 28, 2026Aug 27, 2026
EPS Estimate-------------------------------------
EPS Actual-0.09-0.11-0.12-0.16-0.23-0.30-0.25-0.20-0.18-0.20-0.14-0.10-0.08-0.20-0.33-0.06-0.07-0.08-0.07-0.10-0.04-0.04-0.05-0.04-0.03-0.05-0.05-0.18-0.02-0.02-0.02-0.01-0.01-0.01-0.01-0.00-0.00
Surprise-------------------------------------
Timing---------------------------After-hours---------

Key Statistics & Ratios

Market Cap15.75M
Enterprise Value13.65M
Trailing P/E0.00
Forward P/E0.00
Price / Sales1232.72
Price / Book11.85
EPS-0.01
Book Value0.002
Revenue (TTM)-23.00K
Gross Profit (TTM)0
EBITDA-16.91M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-2242.08%
Return on Assets-81.57%
Shares Outstanding610.49M
Shares Float502.12M
Beta-0.75
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Mar 22, 20181:4